The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition.
Breast cancer
Guidelines
JBCS
Systemic treatment
Journal
Breast cancer (Tokyo, Japan)
ISSN: 1880-4233
Titre abrégé: Breast Cancer
Pays: Japan
ID NLM: 100888201
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
10
08
2023
accepted:
13
09
2023
medline:
23
10
2023
pubmed:
7
10
2023
entrez:
7
10
2023
Statut:
ppublish
Résumé
The Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for systemic treatment of breast cancer were updated to the 2022 edition through a process started in 2018. The updated guidelines consist of 12 background questions (BQs), 33 clinical questions (CQs), and 20 future research questions (FRQs). Multiple outcomes including efficacy and safety were selected in each CQ, and then quantitative and qualitative systematic reviews were conducted to determine the strength of evidence and strength of recommendation, which was finally determined through a voting process among designated committee members. Here, we describe eight selected CQs as important updates from the previous guidelines, including novel practice-changing updates, and recommendations based on evidence that has emerged specifically from Japanese clinical trials.
Identifiants
pubmed: 37804479
doi: 10.1007/s12282-023-01505-x
pii: 10.1007/s12282-023-01505-x
pmc: PMC10587293
doi:
Types de publication
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
872-884Informations de copyright
© 2023. The Author(s).
Références
Ann Oncol. 2001 Sep;12(9):1247-54
pubmed: 11697835
Lancet Oncol. 2021 Feb;22(2):212-222
pubmed: 33460574
J Clin Oncol. 2021 May 10;39(14):1518-1530
pubmed: 33793299
Ann Oncol. 2021 Dec;32(12):1571-1581
pubmed: 34656740
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
Ann Oncol. 2018 Jul 1;29(7):1541-1547
pubmed: 29718092
Breast Cancer Res Treat. 2017 Jan;161(1):63-72
pubmed: 27798749
Oncologist. 2017 Sep;22(9):1028-1038
pubmed: 28652278
Lancet. 2023 Jan 14;401(10371):105-117
pubmed: 36495879
JAMA Oncol. 2020 Jan 01;6(1):116-124
pubmed: 31563959
Breast Cancer. 2020 May;27(3):322-331
pubmed: 32240526
J Clin Oncol. 2020 Nov 10;38(32):3743-3752
pubmed: 32936713
N Engl J Med. 2016 Nov 3;375(18):1738-1748
pubmed: 27717303
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
N Engl J Med. 2018 Nov 15;379(20):1926-1936
pubmed: 30345905
N Engl J Med. 2019 Jul 25;381(4):307-316
pubmed: 31166679
N Engl J Med. 2022 Feb 10;386(6):556-567
pubmed: 35139274
Lancet. 2017 Mar 25;389(10075):1195-1205
pubmed: 28215665
J Clin Oncol. 2014 Nov 20;32(33):3744-52
pubmed: 25332249
N Engl J Med. 2015 Jan 8;372(2):134-41
pubmed: 25564897
Ann Oncol. 2014 Mar;25(3):599-605
pubmed: 24504445
Lancet. 2020 Oct 10;396(10257):1090-1100
pubmed: 32966830
N Engl J Med. 2022 Mar 24;386(12):1143-1154
pubmed: 35320644
Lancet Oncol. 2016 Jan;17(1):90-8
pubmed: 26617202
Lancet Oncol. 2020 Jan;21(1):33-43
pubmed: 31838010
J Clin Oncol. 2021 Aug 1;39(22):2452-2462
pubmed: 33835842
Ann Oncol. 2022 Dec;33(12):1250-1268
pubmed: 36228963
J Clin Oncol. 2011 Dec 1;29(34):4498-504
pubmed: 22025143
Br J Cancer. 2021 Oct;125(9):1217-1225
pubmed: 34480096
Lancet Oncol. 2016 Apr;17(4):425-439
pubmed: 26947331
Breast Cancer. 2020 Jan;27(1):9-16
pubmed: 31659711
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
NPJ Breast Cancer. 2019 Jan 17;5:5
pubmed: 30675515
Breast Cancer. 2020 Jan;27(1):17-24
pubmed: 31734900
J Clin Oncol. 2020 Dec 1;38(34):3987-3998
pubmed: 32954927
Lancet Oncol. 2021 Jan;22(1):74-84
pubmed: 33387497
N Engl J Med. 2011 Oct 6;365(14):1273-83
pubmed: 21991949
J Clin Oncol. 2018 Aug 20;36(24):2465-2472
pubmed: 29860922
N Engl J Med. 2021 Jun 24;384(25):2394-2405
pubmed: 34081848
Breast Cancer. 2020 Jan;27(1):4-8
pubmed: 31832890
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882